Skip to content
OnKommon
OnKommon Twin

Twin FAQs

Questions, answered.

How the Twin is built, how it stays current, and how every decision stays with the treating oncologist.

What makes Twin different

Six things only a Twin can do

  • Built from every input

    Sequencing, clinical history, imaging, labs and symptoms — joined in one living model.

  • 21 proprietary layers

    Each layer answers a different question about the tumour, the patient and the evidence.

  • It keeps learning

    Longitudinal monitoring and quarterly tracks update the Twin as the journey unfolds.

  • Signed by the oncologist

    Every report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.

  • Every option in view

    Therapies, trials and evidence — ranked, sourced and connected to this patient.

  • A 12-year horizon

    Track monitoring every three months keeps the Twin current across a journey of up to 12 years.

The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.

KPCIRC sign-off process

FAQs

Frequently asked questions

What does OnKommon Twin give the oncologist?
A living, structured model of the cancer — molecular findings, clinical context and evidence in one view. The treating oncologist reviews it, signs it and makes every treatment decision.
What is the 'digital twin'?
A living model of everything known about the cancer — built from sequencing, clinical history, imaging and labs, and updated as new information arrives.
How does the Twin stay current?
Through two streams: longitudinal monitoring — every new test, scan or symptom, shared by upload or WhatsApp — and track monitoring, a genetic read every three months across a journey of up to 12 years.
What happens after six months?
At the end of month six the evidence is reviewed and the next step is set. Tracking can continue every three months with Track 12, Track 47 or Track 118 — OnKommon genetic tracking tests, each with its own designed panel and integrated biomarkers.
Who signs the report?
Every Twin report is reviewed and signed by the treating oncologist, and then taken to KPCIRC's internal Molecular Tumour Board.
Do all 21 analytical layers run on every case?
Every case draws on the layers its data supports — RNA layers with RNA data, growth dynamics with repeated measurements — so each Twin uses the layers that matter for that patient.
How are clinical-trial matches found?
TrialGraph matches the patient's biomarkers, cancer type and history against trial registries, ranks the matches and passes them to the treating oncologist. The trial team confirms eligibility at screening.
How long do results take?
It depends on the pathway and the sample. Your care team confirms the timeline for each case.

Still have a question?

Contact usRequest a demonstration

Continue the journey

The 21 analytical layers

Step inside every layer.

→